Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in Anti-GBM Disease
NCT06513338Phase 2Completed
- Sponsor
- Peking University First Hospital
- Start
- Mar 2024
- Primary completion
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of eculizumab in anti-glomerular basement membrane disease, sponsored by Peking University First Hospital. Started Mar 2024; status: completed.
02
Drugs
eculizumab
03
Conditions
anti-glomerular basement membrane disease
Beyond the preview
Go deeper on NCT06513338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06513338.